SPOTLIGHT -
In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.
FDA Grants Accelerated Approval to Breyanzi for Relapsed or Refractory Follicular Lymphoma
This is the second accelerated approval the FDA has granted to Bristol Myers Squibb’s chimeric antigen receptor T-cell therapy in the past few months.
Non-Compete Clauses and the Nursing Shortage: Q&A with Matt Hollingsworth
Carta Healthcare’s co-founder discusses how a recent ruling on non-compete clauses may help alleviate the coming nursing shortage.
FDA Approves Roche’s HPV Self-Collection Solution, Allowing Patients to Gather Their Own Samples in a Healthcare Setting
Roche’s human papillomavirus solution is reportedly one of the first of its kind to be available in the United States.
Leveraging Lessons from Commercialization and Distribution of Rare Products for Cell and Gene Therapy
In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora discusses ways that cell and gene therapy developers can follow examples from the commercialization and distribution of orphan drugs.
FDA Grants Priority Review Biologics License Application to Dupixent Add-On Maintenance for the Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis
Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled.
A Biosimilars Roadmap: Understanding Payer Perceptions
With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.